GREGG STONE, Columbia University, New York
New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone
REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: 2225
JOSEPH MUHLESTEIN, University of Utah , Salt Lake City
Extended follow up of
REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract 1948 (C 206) Page: 236, Sunday 12th
OSCAR C MARROQUIN, University of
CHRISTIAN SPAULDING, Cochin Hospital, Paris
REFERENCE: 4825 “Clinical Trial Update I” Session
Christoph Kaiser, University of Basel
Bare metal stents may be just as effective, and in some lesions even more effective,
The ABT578-eluting ENDEAVOR stent has been compared head-to-head with sirolimus-eluting Cypher. Duke University’s David Kandzari told us more.
Drug-eluting stents should not be the favoured option for treating saphenous vein graft lesions according conclusions from a registry analysis presented to the American Heart Association conference by Jeff Trost from Johns Hopkins in Baltimore.
Bruno Scheller, Universitatsklinikum des Saarlandes, Homburg Saar
A future option for treating in-stent restenosis is the idea of coating a balloon with an anti-proliferative drug and inflating it inside the newly-occluded stent. At the ESC Congress, Bruno Scheller…